JOP20210202A1 - طرق وتركيبات لتطوير منتجات إكسوزوم وعامل نمو نوعية مستهدفة - Google Patents

طرق وتركيبات لتطوير منتجات إكسوزوم وعامل نمو نوعية مستهدفة

Info

Publication number
JOP20210202A1
JOP20210202A1 JOP/2021/0202A JOP20210202A JOP20210202A1 JO P20210202 A1 JOP20210202 A1 JO P20210202A1 JO P20210202 A JOP20210202 A JO P20210202A JO P20210202 A1 JOP20210202 A1 JO P20210202A1
Authority
JO
Jordan
Prior art keywords
methods
growth factor
compositions
target specific
specific exosome
Prior art date
Application number
JOP/2021/0202A
Other languages
Arabic (ar)
English (en)
Inventor
Timothy Alexander Moseley
Kenneth Allen Pettine
Original Assignee
Direct Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direct Biologics Llc filed Critical Direct Biologics Llc
Publication of JOP20210202A1 publication Critical patent/JOP20210202A1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0663Bone marrow mesenchymal stem cells (BM-MSC)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/985Skin or skin outgrowth, e.g. hair, nails
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0666Mesenchymal stem cells from hair follicles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/124Animal traits, i.e. production traits, including athletic performance or the like
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Birds (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
JOP/2021/0202A 2019-01-30 2020-01-30 طرق وتركيبات لتطوير منتجات إكسوزوم وعامل نمو نوعية مستهدفة JOP20210202A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962798908P 2019-01-30 2019-01-30
PCT/US2020/015982 WO2020160342A1 (en) 2019-01-30 2020-01-30 Methods and compositions for developing target specific exosome and growth factor products

Publications (1)

Publication Number Publication Date
JOP20210202A1 true JOP20210202A1 (ar) 2023-01-30

Family

ID=71842346

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0202A JOP20210202A1 (ar) 2019-01-30 2020-01-30 طرق وتركيبات لتطوير منتجات إكسوزوم وعامل نمو نوعية مستهدفة

Country Status (13)

Country Link
US (1) US20220136053A1 (https=)
EP (1) EP3917489A4 (https=)
JP (2) JP2022535178A (https=)
KR (1) KR20210121183A (https=)
AU (1) AU2020214832A1 (https=)
BR (1) BR112021014994A2 (https=)
CA (1) CA3128050A1 (https=)
IL (1) IL285228A (https=)
JO (1) JOP20210202A1 (https=)
MX (1) MX2021009254A (https=)
SG (1) SG11202108129SA (https=)
WO (1) WO2020160342A1 (https=)
ZA (1) ZA202105483B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞(msc)の調製物を含む助剤、ならびにその使用方法
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
JP2023180556A (ja) * 2022-06-09 2023-12-21 日本メナード化粧品株式会社 薄毛の遺伝的素因の判定方法
WO2024233684A2 (en) * 2023-05-08 2024-11-14 Vitti Labs Methods of treating ovarian conditions and diseases
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
CN118516305B (zh) * 2024-07-22 2024-11-26 深圳大学 力学信号调控下的外泌体制备方法、外泌体及其在骨、软骨再生修复领域的应用
CN120899659A (zh) * 2025-08-06 2025-11-07 河北医科大学第三医院 一种过表达cap基因和lgr5基因的外泌体在制备治疗软骨炎症药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090177487A1 (en) * 2008-01-07 2009-07-09 Tera Eerkes Methods for Assessing Genetic Compatibility
CN102014934B (zh) * 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
ES2746554T3 (es) * 2010-11-02 2020-03-06 Univ Columbia Métodos para tratar los trastornos de pérdida de cabello
US20130129688A1 (en) * 2011-11-09 2013-05-23 Allocure, Inc. Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same
CA2866563A1 (en) * 2012-03-07 2013-09-12 Fibrocell Technologies, Inc. Topical dermal formulations and methods of personalized treatment of skin
EP3270984A4 (en) * 2015-03-16 2019-04-17 Duncan Ross TREATMENT METHOD WITH MEMBRANE-INCLUDED VESICLE
AU2016261358B2 (en) * 2015-05-11 2021-09-16 Editas Medicine, Inc. Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
MX2019005127A (es) * 2016-11-03 2019-09-26 Exostem Biotec Ltd Poblaciones y productos de células madre mesenquimales y sus usos.
US10987381B2 (en) * 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis
WO2018162696A1 (en) * 2017-03-10 2018-09-13 Institut Pasteur Common genetic variations at the tcra-tcrd locus control thymic function in humans
JP2021526556A (ja) * 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞(msc)の調製物を含む助剤、ならびにその使用方法
KR20210121039A (ko) * 2018-12-26 2021-10-07 다이렉트 바이오로직스 엘엘씨 피부 및 모발 장애를 치료하기 위한 방법 및 조성물

Also Published As

Publication number Publication date
KR20210121183A (ko) 2021-10-07
SG11202108129SA (en) 2021-08-30
BR112021014994A2 (pt) 2021-10-05
JP2022535178A (ja) 2022-08-05
EP3917489A1 (en) 2021-12-08
CA3128050A1 (en) 2020-08-06
US20220136053A1 (en) 2022-05-05
JP2025037913A (ja) 2025-03-18
MX2021009254A (es) 2021-09-28
IL285228A (en) 2021-09-30
ZA202105483B (en) 2022-07-27
WO2020160342A1 (en) 2020-08-06
AU2020214832A1 (en) 2021-08-19
EP3917489A4 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
JOP20210202A1 (ar) طرق وتركيبات لتطوير منتجات إكسوزوم وعامل نمو نوعية مستهدفة
SA521421188B1 (ar) بروتينات رابطة متعددة النوعية ترتبط بـ her2 -nkg2d -cd16، وطرق استخدامها
MX2018015683A (es) Composiciones y métodos para el agotamiento de células.
JOP20210154A1 (ar) مثبطات kif18a
MX2021007104A (es) Inhibidores de kif18a.
MY207784A (en) Anti-cd73 antibodies
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
MX2021015337A (es) Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
MX2018015684A (es) Composiciones y metodos para el agotamiento de celulas cd117.
NZ707831A (en) Agents for treatment of claudin expressing cancer diseases
PH12021500031A1 (en) Anti-il2 receptor gamma antigen-binding proteins
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
EA202091360A1 (ru) Гуманизированные анти-liv1 антитела для лечения рака молочной железы
NZ761094A (en) Diaryl macrocycles as modulators of protein kinases
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
AU2017257153A1 (en) Sigma receptor binders
PH12022553147A1 (en) Methods and means for the production of ig-like molecules
AR101735A1 (es) Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro)
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2023002106A (es) Anticuerpos fgfr3 y metodos de uso.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
CL2022001006A1 (es) Inhibidores de tim-3 y sus usos
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
EA201500670A1 (ru) Egfr-направленная терапия неврологических нарушений и боли